Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Study: Investigational drug shows promise against pancreatic cancer

Study: Investigational drug shows promise against pancreatic cancer

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Leukemia drug reverses symptoms of colitis in lab tests

Leukemia drug reverses symptoms of colitis in lab tests

A simple blood test may reveal the earliest signs of pancreatic cancer

A simple blood test may reveal the earliest signs of pancreatic cancer

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Study: Elevated BMI may affect survival in pancreatic cancer patients

Study: Elevated BMI may affect survival in pancreatic cancer patients

Pancreatic cancer patients may benefit from antibody-drug conjugates

Pancreatic cancer patients may benefit from antibody-drug conjugates

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Whitehead Institute scientists discover insidious nature of influenza virus

Whitehead Institute scientists discover insidious nature of influenza virus

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

NEJM publishes Celgene’s Abraxane phase III study results

NEJM publishes Celgene’s Abraxane phase III study results

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Noninvasive tool created to detect pancreatic cancer through risk assessment test using saliva

Noninvasive tool created to detect pancreatic cancer through risk assessment test using saliva

Gemcitabine drug improves survival rates in patients with pancreatic cancer

Gemcitabine drug improves survival rates in patients with pancreatic cancer

Six prominent surgeons awarded Honorary Fellowship at Clinical Congress of ACS

Six prominent surgeons awarded Honorary Fellowship at Clinical Congress of ACS

New biomarker for pancreatic cancer effectively targets potential therapy for small survival rate

New biomarker for pancreatic cancer effectively targets potential therapy for small survival rate

Study shows direct causative link between obesity and risk of pancreatic cancer in mice

Study shows direct causative link between obesity and risk of pancreatic cancer in mice

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.